TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05008718

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 38% SDF group
Description: Participants will be randomized and will receive either 38% SDF treatment or 5% NaF treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 5% NaF group
Description: Participants will be randomized and will receive either 38% SDF treatment or 5% NaF treatment
Study: NCT06589505

Intervention type: DEVICE
Group type: OTHER
Intervention: Software as a Medical Device
Description: The subject will undergo treatment using the Software as a Medical Device
Study: NCT05044104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Consumer-facing wearable smart watch
Description: Wearable watch technology that has the ability to measure heart rate, respiratory rate, single-lead electrocardiography, and blood oxygen saturation.
Study: NCT05529355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab plus Endostar and S-1
Description: Immunotherapy combined with chemotherapy and anti VEGFR therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Envafolimab plus Endostar
Description: Immunotherapy combined with anti VEGFR therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Envafolimab plus S-1
Description: Immunotherapy combined with chemotherapy
Study: NCT06245239

Intervention type: DEVICE
Intervention: perfusion index
Description: measurement of perfusion index
Study: NCT05781958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab+Gem/Cis
Description: Cadonilimab (500mg, iv, Q3W, Day1) with gemcitabine(1000mg/m\^2, iv, Q3W, Day1and Day8) plus cisplatin(25mg/m\^2, iv, Q3W, Day1and Day8) up to 8 cycles followed by cadonilimab (500mg, iv, Q3W, Day1) plus capecitabine（1000 mg/m\^2 orally according to Body Surface Area (BSA)，BID，Q3W，on Days 1-14）as maintenance therapy until disease progression or other discontinuation criteria, up to 24months.
Study: NCT05133713

Intervention type: DEVICE
Intervention: Catheter directed therapy
Description: Thrombectomy
Study: NCT04826770

Intervention type: DRUG
Intervention: BNT162b2
Description: vaccination against COVID-19

Intervention type: DRUG
Intervention: AZD 1222
Description: vaccination against COVID-19

Intervention type: DRUG
Intervention: AZD 1222
Description: vaccination against COVID-19

Intervention type: DRUG
Intervention: AZD 1222
Description: vaccination against COVID-19
Study: NCT04634851

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual home visits
Description: These participants will have a tailored evaluation of dietary choices based on their home dietary environment (refrigerator, pantry, etc). This will be conducted over video exchange.
Study: NCT04826770

Intervention type: DRUG
Intervention: AZD 1222
Description: vaccination against COVID-19

Intervention type: DRUG
Intervention: mRNA-1273
Description: vaccination against COVID-19

Intervention type: DRUG
Intervention: mRNA-1273
Description: vaccination against COVID-19
Study: NCT05054959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: consolidation chemotherapy
Description: 6 cycles CAPOX after chemoradiotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: induction chemotherapy
Description: 4 cycles CAPOX before and 2 cycles CAPOX after chemoradiotherapy
Study: NCT05133713

Intervention type: DRUG
Intervention: Systemic anticoagulation
Description: Conservative therapy

Intervention type: DRUG
Intervention: Systemic anticoagulation
Description: Conservative therapy
Study: NCT04774471

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of BIT-Motion software
Description: Software program to discern benign versus malignant breast lesions.
Study: NCT04759703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: 0.25 mg pramipexole tablets
Study: NCT06205836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Patients will receive cemiplimab (350 mg administered IV) on Day 1 of each 21 day cycle for a total of 4 cycles of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Patients will receive cemiplimab (350 mg administered IV) on Day 1 of each 21 day cycle for a total of 4 cycles of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fianlimab
Description: Patients will receive fianlimab (1600 mg administered IV) on Day 1 of each 21 day cycle for a total of 4 cycles of treatment.
Study: NCT05256797

Intervention type: DRUG
Intervention: Rivaroxaban
Description: Any rivaroxaban dispensing claim is used as the reference group

Intervention type: DRUG
Intervention: Apixaban
Description: Any apixaban dispensing claim is used as the exposure group
Study: NCT04944368

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
Description: SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: 0.9% sodium chloride (1 mL) injection in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
Study: NCT05981937

Intervention type: DRUG
Intervention: ICG solution
Description: ICG-ATT is available at our institute since 2019 using a near-infrared (NIR) light source and special scope and camera equipped with xenon light (CARL STORZ GmbH \& Co. KG, Tuttlingen, Germany); ICG was supplied as a sterile water-soluble lyophilized powder (Diagnostic Green® GmbH). ICG-ATT is routinely used whenever available in daily practice with the following protocol: after the specimen resection the two colonic stumps or colonic and rectal stumps are checked with 5 cc of ICG 25 mg diluted in 10 cc of water sterile solution before fashioned anastomosis. Two laparoscopes with ICG-optic system are nowadays available department and ICG anastomosis control is always performed if ICG device are available (no performed in case of not available ICG instrument for sterilization in case of two consecutive surgery in the same day, concomitant ICG surgery or ICG malfunction).
Study: NCT05748704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-term modified fasting
Description: STMF regimen consists of a low-calorie diet aimed at providing 800-1,000 kcal/day, lasting five days and with the following composition: 10% carbohydrates, 15% proteins, 75% lipids. During the days of STMF, patients will be required to write down the foods consumed in a food diary in order to calculate calorie and nutrients intake. The STMF regimen will be administered tentatively on a monthly basis (depending on the therapeutic regimen the patient undergoes) and in any case no more frequently than once every three weeks.
Study: NCT05178329

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifting exercise
Description: Patients are instructed for a light lifting exercise after mastectomy.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard exercise
Description: Standard exercise program after mastectomy
Study: NCT05948722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview Group (MIG)
Description: Brief MI intervention with the conventional treatment
Study: NCT05654688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: graston and muscle energy technique
Description: Graston technique (Gt) is a technique of mobilization of soft tissue using instruments which consider myofascial release instrument that has been reported to relieve pain, improve overall function, and increase range of motion.~Muscle energy technique (MET) is a term composed of various types of active muscular relaxation and stretching procedures. The two cornerstone forms of MET are reciprocal inhibition and post isometric relaxation. In theory, reciprocal inhibition takes advantage of the neurological phenomena of muscular contraction, which results in an inhibitory effect on the antagonistic muscles.
Study: NCT04689932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic AVNU
Description: Ferric Pyrophosphate Citrate
Study: NCT05433441

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESPark Intervention
Description: The treatment will include 15 sessions (1 session per week). An initial assessment will be carried out during the first session in order to determine the objectives and the personalized follow-up.
Study: NCT04996407

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: survival thermal blanket
Description: patients were given a thermal blanket

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: survival thermal blanket
Description: patients were given a thermal blanket

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: draping fabric
Description: Patients were given a draping fabric
Study: NCT04759703

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets
Study: NCT05654688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: graston and muscle energy technique
Description: Graston technique (Gt) is a technique of mobilization of soft tissue using instruments which consider myofascial release instrument that has been reported to relieve pain, improve overall function, and increase range of motion.~Muscle energy technique (MET) is a term composed of various types of active muscular relaxation and stretching procedures. The two cornerstone forms of MET are reciprocal inhibition and post isometric relaxation. In theory, reciprocal inhibition takes advantage of the neurological phenomena of muscular contraction, which results in an inhibitory effect on the antagonistic muscles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: graston and muscle energy technique
Description: Graston technique (Gt) is a technique of mobilization of soft tissue using instruments which consider myofascial release instrument that has been reported to relieve pain, improve overall function, and increase range of motion.~Muscle energy technique (MET) is a term composed of various types of active muscular relaxation and stretching procedures. The two cornerstone forms of MET are reciprocal inhibition and post isometric relaxation. In theory, reciprocal inhibition takes advantage of the neurological phenomena of muscular contraction, which results in an inhibitory effect on the antagonistic muscles.
Study: NCT04996407

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: draping fabric
Description: Patients were given a draping fabric
Study: NCT05948722

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment group (CTG)
Description: Conventional treatment
Study: NCT05981872

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: rehacom
Description: Rehacom was carried out at the cognition laboratory at Faculty of physical therapy, Cairo University for training of figural memory, attention concentration.~1. Attention concentration training consists of 24 levels of difficulties .~2. Figural memory training consists of 9 levels of difficulties. In the training session, every patient was starting training from level one and when the patient successfully finished the level, the training then Progress to the level of difficulty.
Study: NCT05873036

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Aerobic Training
Description: Aerobic Training to Improve Functional Ability After Breast Cancer Surgery

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training
Description: Progressive Resistance Training to Improve Functional Ability After Breast Cancer Surgery
Study: NCT05057442

Intervention type: OTHER
Intervention: Proprioception assessment, functionality assessment
Description: Proprioception assessment, functionality assessment
Study: NCT05701774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCCR
Description: Once daily oral administration
Study: NCT05113615

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium Bromide
Description: respimat inhaler 2.5mcg/puff

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: matching placebo Respimat inhaler
Study: NCT05735522

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal magnetic stimulation
Description: Extracorporeal magnetic stimulation is a technique based on Faraday's law of magnetic induction, approved by the United States Food and Drug Administration in 1998, for conservative treatment of urinary incontinence. It generates electrical activity, which induces controlled depolarization of the nerves, resulting in pelvic muscle contraction and sacral S2-S4 roots neuromodulation. The patient seats in the chair fully clothed.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The same chair as is used in the active group with the magnetic field density at the lower 2% resulting in negligible efficacy.
Study: NCT05981872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rehacom
Description: Rehacom was carried out at the cognition laboratory at Faculty of physical therapy, Cairo University for training of figural memory, attention concentration.~1. Attention concentration training consists of 24 levels of difficulties .~2. Figural memory training consists of 9 levels of difficulties. In the training session, every patient was starting training from level one and when the patient successfully finished the level, the training then Progress to the level of difficulty.
Study: NCT04799340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive training
Description: training to improve encoding and recognition of faces
Study: NCT06504433

Intervention type: DIAGNOSTIC_TEST
Intervention: Confirmed variant/deletion in either nuclear or mitochondrial genes involved in the mitochondrial respiratory chain
Description: This is a 10-year, longitudinal, non-randomised, retrospective and prospective, observational study that will be used to characterise the natural history of primary mitochondrial disease (MITO) in 400 participants and their asymptomatic family members (with no genetic risk), non-MITO healthy controls (100 participants) and form a biobank that can be used in future research using separate ethics approved protocols to identify biomarkers of disease onset and progression.
Study: NCT06489795

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic or robot-assisted radical/simple hysterectomy
Description: In the experimental arm, patients with early-stage cervical cancer will be treated by using laparoscopic or robot-assisted radical, or in the case of SHAPE criteria, simple hysterectomy.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Abdominal radical/simple hysterectomy
Description: In the control arm, patients with early-stage cervical cancer will be treated by using abdominal radical, or in the case of SHAPE criteria, simple hysterectomy as standard therapy.
Study: NCT06504433

Intervention type: DIAGNOSTIC_TEST
Intervention: Confirmed variant/deletion in either nuclear or mitochondrial genes involved in the mitochondrial respiratory chain
Description: This is a 10-year, longitudinal, non-randomised, retrospective and prospective, observational study that will be used to characterise the natural history of primary mitochondrial disease (MITO) in 400 participants and their asymptomatic family members (with no genetic risk), non-MITO healthy controls (100 participants) and form a biobank that can be used in future research using separate ethics approved protocols to identify biomarkers of disease onset and progression.

Intervention type: DIAGNOSTIC_TEST
Intervention: Confirmed variant/deletion in either nuclear or mitochondrial genes involved in the mitochondrial respiratory chain
Description: This is a 10-year, longitudinal, non-randomised, retrospective and prospective, observational study that will be used to characterise the natural history of primary mitochondrial disease (MITO) in 400 participants and their asymptomatic family members (with no genetic risk), non-MITO healthy controls (100 participants) and form a biobank that can be used in future research using separate ethics approved protocols to identify biomarkers of disease onset and progression.
Study: NCT05297487

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: early use of intermittent positive pressure breathing
Description: standard care associated with daily and early use of intermittent positive pressure breathing
Study: NCT05081947

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: COMPASS
Description: COMPASS is a web-based intervention (online CBT program) that was developed for managing illness-related anxiety and depression in patients with long-term conditions (LTC) (https://compass-ltc.org/). An example of the patient login page can be viewed here: www.compass-southwark.co.uk. COMPASS aims to support people in managing the challenges of living with a long-term condition. COMPASS is based on research which shows the benefit of combining mental and physical healthcare. The proposed COMPASS program consists of 11 online sessions for patients to work through over approximately 12 weeks. The sessions can be worked through in any order the patient would like. The sessions are split into four quadrants - North, East, South and West - which explore different elements of managing the LTC challenges that were identified from the evidence-based systematic review. Sessions contain information, interactive tasks, goal setting and patient stories.
Study: NCT05985278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [ Lu-177]-Catalase
Description: \[ 177Lu\]-Catalase is administered by intratumoral puncture every four weeks, and the specific dose is related to the size of the tumor
Study: NCT06422858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Serplulimab will be administered as a fixed dose of 300 mg via intravenous infusion every three weeks, continuing for up to 12 months or until disease progression, unacceptable toxicity, or withdrawal of consent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur-gimeracil-oteracil potassium capsule(S1)
Description: S1 will be administered at a dose of 60 mg/m2 per day, taken orally in two divided doses on day 1 concurrent with radiotherapy, repeated every 28 days; and from day 1 to day 14 of each 21-day cycle, for up to 12 months or until disease progression, unacceptable toxicity, or withdrawal of consent

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will be delivered as a total dose of 50.4 Gy in 28 fractions over six weeks using techniques such as IGRT, IMRT, VMAT, or TOMO, targeting the primary tumor and associated lymph nodes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered at a dose of 75 mg/m\^2 on day 1 concurrent with radiotherapy, repeated every 28 days
Study: NCT06536205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducation
Description: Psychoeducation, psychological difficulties or physical diseases; These are structured educational interventions aimed at teaching people about their illness and their emotional responses to the illness, developing coping skills, ensuring compliance with the illness and cooperation with treatment.
Study: NCT04790812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Single, preemptive oral dose 200mg of celecoxib. A cyclooxygenase-2 (COX-2) selective inhibitor for pain management. A COX-2 selective nonsteroidal anti-inflammatory drug (NSAID).
Study: NCT05523661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib plus anti-CD19/CD22 CAR-T cells
Description: Dasatinib plus VP chemotherapy was administrated to newly diagnosed Ph-positive patients aged 55-70 years old,if hCR was achieved,autolymphocyte was collected,and anti-CD19/CD22 CAR-T cells infusion was administrated to patients followed by Fludarabine and Cyclophosphamide therapy
Study: NCT06625892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the multidimensional interventions
Description: The study participants will receive cognitive behavior therapy intervention for six weeks, one session per week, 45 minutes each time, and exercise training for twelve weeks, twice sessions per week, 60 minutes each time.
Study: NCT06634095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moulage group
Description: The experimental group is trained with a moulage-supported standardized patient simulation. Participants in the experimental group practice during the specified moulage-supported standardized patient simulation. Moulage-supported simulations regarding pressure ulcers will be created and training will be provided.
Study: NCT06632717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Chemotherapy regimen~• Cisplatin 60mg/m2 on day 2; 5-fluorouracil (5-FU) 500mg/m2 on day 1 - day 3 via the HAIC port, every 3 weeks until progression or intolerable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Chemotherapy regimen~• Cisplatin 60mg/m2 on day 2; 5-fluorouracil (5-FU) 500mg/m2 on day 1 - day 3 via the HAIC port, every 3 weeks until progression or intolerable toxicity

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipiodol embolization
Description: Lipiodol embolization protocol~* Lipiodol embolization will be performed on day 3 after completion of 5-FU infusion, up to 4 cycles. Fixed dose lipiodol of 10mL will be given on day 3 followed by 30mL normal saline flush.~* The administration of lipiodol is mandatory on cycle 1. The administration of lipiodol on cycle 2 to cycle 4 will depend on the discretion of the treating physician and the presence of adverse effects from lipiodol embolization.
Study: NCT06633783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: The dose escalation phase, starting with 0.25mg once weekly and increasing every 4 weeks (0.5mg, 1.0mg, 1.7mg), is expected to last 16 weeks; In the dose maintenance phase, the target dose of 2.4mg was maintained for 28 weeks.Treatment duration 44 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: The dose escalation phase, starting with 0.25mg once weekly and increasing every 4 weeks (0.5mg, 1.0mg, 1.7mg), is expected to last 16 weeks; In the dose maintenance phase, the target dose of 2.4mg was maintained for 28 weeks.Treatment duration 44 weeks.
Study: NCT04790812

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celecoxib
Description: Single, preemptive oral dose 200mg of celecoxib. A cyclooxygenase-2 (COX-2) selective inhibitor for pain management. A COX-2 selective nonsteroidal anti-inflammatory drug (NSAID).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Single, preemptive oral dose 1000mg of acetaminophen. An over-the-counter medication for pain management.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A capsule with no active ingredients designed to mimic the appearance of the acetaminophen capsule to ensure blinding of patients and care providers.